Live Breaking News & Updates on Proteasome Inhibitor

Stay updated with breaking news from Proteasome inhibitor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Belantamab Mafodotin Tops Daratumumab in Multiple Myeloma

The phase 3 study findings supported belantamab mafodotin as a potential new standard of care in the second line or later among patients with released/refractory multiple myeloma. ....

Castillay Leóp , Maria Victoria Mateos , University Hospital Of Salamanca , University Hospital , Multiple Myeloma , Plasma Cell Myeloma , Proteasome Inhibitor , Biologic Therapy , Anemia Anaemia , Monoclonal Antibody ,

Idecabtagene Vicleucel Approaches EU Approval in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

The EMA's CHMP has recommended the approval of idecabtagene vicleucel in patients with multiple myeloma who received at least 2 prior therapies. ....

Anne Kerber , International Staging System , Oncologic Drugs Advisory Committee , Late Clinical Development , European Commission , Bristol Myers Squibb , European Medicines Agency , Medicinal Products , Human Use , Cell Therapy , Revised International Staging System , Drugs Advisory Committee , Myers Squibb , Idecabtagene Vicleucel , Ide Cel , Multiple Myeloma , Committee For Medicinal Products Human Use , Karmma 3 Study , Cart Cell Therapy , Car T , Immunomodulatory Drug , Proteasome Inhibitor , Anti Cd38 Monoclonal Antibody ,

This Frontline Therapy Is Better in Multiple Myeloma: Study

A study directly comparing real-world outcomes suggests patients with transplant-ineligible multiple myeloma do better with frontline triple therapy with daratumumab vs bortezomib. ....

United States , Dorisk Hansen , American Society Of Hematology , National Comprehensive Cancer Network , Moffitt Cancer Center Research Institute In Tampa , Moffitt Cancer Center , Research Institute , American Society , Multiple Myeloma , Plasma Cell Myeloma , Monoclonal Antibody , Biologic Therapy , Proteasome Inhibitor , Transplantation Of Stem Cells , Ransplantation Of Hematopoietic Stem Cells , Hematopoietic Stem Cell Transplant , Stem Cell Transplantation , Stem Cell Therapy , Tem Cell Haematopoietic Stem Transplant ,

Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity

'This [research] builds on our experience that four-drug combinations with a monoclonal antibody, proteasome inhibitor, immunomodulatory drug, and steroids are superior to three-drug combinations.' ....

United States , Dana Farber Cancer Institute , Bristol Myers Squibb Celgene , Joseph Mikhael , Irene Ghobrial , City Of Hope Cancer Center , American Society Of Hematology , University Of Torino , International Myeloma Foundation , Division Of Hematology , Translational Genomics Research Institute Tgen , Health Sciences , Department Of Molecular Biotechnology , Translational Genomics Research Institute , Hope Cancer Center , American Society , Francesca Gay , Molecular Biotechnology , Medical Oncology , Bristol Myers , Multiple Myeloma , Plasma Cell Myeloma , Biologic Therapy , Monoclonal Antibody , Proteasome Inhibitor , Autologous Stem Cell Transplant ,

ELREXFIO™ (elranatamab-bcmm), Now Available from Onco360

ELREXFIO™ (elranatamab-bcmm), Now Available from Onco360
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Benito Fernandez , National Cancer Institute Surveillance , National Comprehensive Cancer Network , Pfizer Inc , End Results Program , Pharmerica Corporation , Drug Administration , Has Received , Accelerated Approval , Adult Patients With Relapsed , Refractory Multiple Myeloma Who Have Received , Least Four Prior Lines , Therapy Including , Proteasome Inhibitor , Specialty Pharmacy , Chief Commercial , National Cancer Institute , End Results , United States Food , Risk Evaluation , Mitigation Strategy , Cytokine Release Syndrome , Oncology Pharmacy , Accessed August , Comprehensive Cancer Network ,